Specialty Pharmacy

Top news of the day from across the health care landscape

The Ensuring Seniors Access to Local Pharmacies Act, which was recently reintroduced, would allow more “preferred” pharmacies in medically underserved areas.

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

Lumacaftor-ivacaftor (Orkambi) improves lung health in patients with cystic fibrosis who tolerate the treatment, but discontinuation rates may pose a risk of deterioration.

Top news of the day from across the health care landscape

A new computer method could help reveal the origins of Crohn disease and improve early diagnosis and accuracy.

Early treatment with lenalidomide in patients with smoldering multiple myeloma may help delay onset of myeloma-related bone and organ damage.

The FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions.

Top news of the day from across the health care landscape

Men treated with stereotactic ablative radiotherapy found to live significantly longer without any detectable disease progression compared with patients who received no additional treatment.

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.

Study suggests that men who use assisted reproduction techniques may benefit from early screening and long-term monitoring for prostate cancer.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.

At the ESMO Congress 2019, Eileen O'Reilly, MD, from Memorial Sloan Kettering Cancer Center, discussed the common themes among emerging therapies in the advanced pancreatic cancer setting.

Ron Lanton III, Esq., discusses the specialty pharmacist's role in educating patients about biosimilars and biologics.

National Institutes of Health experts discuss optimization of existing strategies for HIV treatment and prevention, as well as the development of new approaches.

Patients with non-Hodgkin lymphoma were more likely to discontinue treatment early when prescribed rituximab by physicians who had less experience with the drug.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Ron Lanton III, Esq., discusses challenges in launching biosimilars after they've been approved.

Psoriasis may increase the risk of cancer incidence and cancer-related mortality in affected individuals.

Effective December 31, 2019, Amgen’s 60% annual list price cut for evolocumab (Repatha) will be fully implemented.

Top news of the day from across the health care landscape.

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.